Development, manufacturing, and sales of test and diagnostic systems in the biopharmaceutical field.EquipmentSoftwareReagentsConsumablesMaintenanceContract testingmagLEAD seriesgeneLEAD seriesLuBEA seriesLecChip seriesReagent lineup
Names without a link are companies not yet registered in OpenBizGraph
§05
Network
NETWORK
Loading the relationship graph...
Drag to move · click to open
§06
History
106 EVENTS
Established in Itabashi-ku, Tokyo, for the purpose of maintenance and servicing of physical and chemical equipment (clinical laboratory instruments).
Founded as a maintenance and service company for clinical laboratory instruments at Itabashi-Ku, Tokyo.
Relocated headquarters to Fuchu City, Tokyo.
The Head Office was transferred to Fuchu-city, Tokyo.
Commenced manufacturing and sales of in-house products such as dispensing, dilution, and cleaning equipment for physical and chemical instruments.
Starting the production and sales of clinical laboratory instruments such as fractionating devices, dilution apparatuses and washing apparatuses started as PSS own products.
Established Matsudo Research Laboratory in Matsudo City, Chiba Prefecture as a research and development facility.
Matsudo Research Laboratory was founded in Matsudo, Chiba, as a research and development facility.
Relocated headquarters to Inagi City, Tokyo.
The Head Office was transferred to Inagi-city, Tokyo.
Successfully commercialized a chemiluminescent immunoassay device (HiMICO) using magnetic particle method. Filed patents for the development technology in Japan, the United States, Europe, and other countries worldwide, naming it MagTraction Technology.
Successfully commercialized the immunochemical luminescence measuring system (HiMICO) using magnetic particles technology. The invented technology was applied for patent in various countries including Japan, U.S., and Europe, and was named "Magtration : ® : Technology".
Successfully commercialized the immunochemical luminescence measuring system (HiMICO) using magnetic particles technology. The invented technology was applied for patent in various countries including Japan, U.S., and Europe, and was named 'Magtration Technology'.
Successfully commercialized DNA automatic extraction devices and related products using MagTraction Technology.
Successfully commercialized the automated DNA extraction system using the Magtration : ® : Technology.
Successfully commercialized the automated DNA extraction system using the Magtration Technology.
Entered into an OEM agreement with Toyo Bōseki Co., Ltd. regarding DNA automatic extraction devices and related products.
Entered an OEM contract as for Automated DNA extraction system and others with TOYOBO. Co., Ltd. (JAPAN).
Signed an OEM agreement with Swiss F. Hoffmann-La Roche Ltd regarding DNA automatic extraction devices, etc.
Entered an OEM contract as for Automated DNA extraction system and others with F. Hoffmann-La Roche Ltd. (Switzerland).
Signed an OEM agreement with German Boehringer Mannheim GmbH (currently Roche Diagnostics Ltd (Switzerland)) regarding DNA automatic extraction devices, etc.
Entered an OEM contract as for Automated DNA extraction system and others with Boehringer Mannheim GmbH (Germany) (currently, Roche Diagnostics Ltd. (Switzerland)).
Signed an OEM agreement with Norwegian GenoVision AS (now Qiagen AS) regarding DNA automatic extraction devices, etc.
Entered an OEM contract as for Automated DNA extraction system and others with GenoVision AS (Norway) (currently, Qiagen AS).
The Japanese Red Cross Society introduced NAT testing (Nucleic Acid Amplification Test) for blood donations for the first time in the world, utilizing PSS's OEM supplied product (nucleic acid automatic extraction device), which significantly reduced the incidence of post-transfusion hepatitis, thereby contributing to society.
Japan Red Cross implemented 'NAT test(Nucleic Acids Amplification test)' to donated blood for the first time in the world, and the PSS system was the answer. PSS is a leader in helping to reduce serum hepatitis incidence after transfusions.
Signed an OEM agreement with Swedish Magnetic Biosolution Sweden AB regarding DNA automatic extraction devices, etc.
Entered an OEM contract as for Automated DNA extraction system and others with Magnetic Biosolution Sweden AB (Sweden).
Listed shares on the Osaka Stock Exchange Nasdaq Japan Market (now JASDAQ Market).
IPO at OSE NASDAQ Japan Market (currently "JASDAQ" Market).
IPO at OSE NASDAQ Japan Market (currently 'JASDAQ' Market).
Integrated the headquarters in Inajō City with the Matsudo Research Institute into a new headquarters building, relocating the headquarters to Matsudo City, Chiba Prefecture.
Head Office transferred to Matsudo-city, Chiba, where all facilities including Matsudo Research Laboratory were incorporated in the new office building.
Established U.S. subsidiary PSS Bio Instruments, Inc. (California, USA; renamed Precision System Science USA, Inc. in July 2007, dissolved March 2025) and European subsidiary Precision System Science Europe GmbH (Munich, Germany; currently Düsseldorf, Germany).
Established PSS Bio Instruments, Inc. (California,U.S.A. July 2007: Renamed to Precision System Science USA, Inc.,dissolved in March 2025) and : Precision System Science Europe GmbH : (initially located in Mainz, Germany; now in Düsseldorf, Germany).
Established PSS Bio Instruments, Inc. (California, U.S.A.) and Precision System Science Europe GmbH (initially located in Mainz, Germany; now in Düsseldorf, Germany).
Established subsidiary Universal Bio Research Co., Ltd. (Matsudo City, Chiba Prefecture) (excluded from consolidation due to share transfer in January 2025).
Established Universal Bio Research Co., Ltd. (Matsudo, Chiba, Japan); excluded from consolidation after share transfer in January 2025.
Signed an OEM agreement with Norwegian Qiagen AS and German Qiagen GmbH regarding DNA automatic extraction devices, etc. (currently renewed contract with Swiss Qiagen Instruments AG).
Signed an OEM agreement with Mitsubishi Chemical Yatron Co., Ltd. (now LSI Medience Co., Ltd.) regarding a small-scale immunochemical luminescence measurement device.
- 2004 : August : Entered an OEM contract as for compact immunochemical luminescence measuring system with Mitsubishi Kagaku Iatron Inc. (currently, LSI Medience Corp.).
Entered an OEM contract as for compact immunochemical luminescence measuring system with Mitsubishi Kagaku Iatron Inc. (currently, LSI Medience Corp.).
Signed an OEM agreement with Invitrogen Corporation (now Life Technologies Corporation) regarding DNA automatic extraction devices, etc.
- 2006 : May : Entered an OEM contract as for Automated DNA extraction system and others with Invitrogen Corporation (U.S.) (currently, Life Technologies Corporation).
Entered an OEM contract as for Automated DNA extraction system and others with Invitrogen Corporation (U.S.) (currently, Life Technologies Corporation).
Established subsidiary PSS Capital Co., Ltd. as an investment company, under which the Bio Content Investment Business LLC is established and operated.
Signed an OEM agreement with Bechman Coulter, Inc. (USA) regarding DNA automatic extraction devices, etc.
Signed an OEM agreement with NanoString Technologies, Inc. (USA) regarding sample purification and reaction processing systems.
- 2007 : February : Entered an OEM contract as for sample purification-reaction treatment system with NanoString Technologies, Inc. (U.S.)
Entered an OEM contract as for sample purification-reaction treatment system with NanoString Technologies, Inc. (U.S.)
Signed a domestic exclusive sales agreement with GE Healthcare BioScience Co., Ltd. for protein automatic purification devices and reagent kits (Purelumn system).
Collaborated with Belgian Diagenode SA and Nippon Gene Co., Ltd. on the development of automation systems for epigenetics.
- 2008 : April : Entered a collaboration with Diagenode SA (Belgium) and Nippon Gene Co., Ltd. in development of automated system for epigenetics.
Entered a collaboration with Diagenode SA (Belgium) and Nippon Gene Co., Ltd. in development of automated system for epigenetics.
Acquired a portion of shares in NPS Co., Ltd. (applying the equity method) and established a partnership with Japan Pulse Motor Co., Ltd.
- 2009 : September : PSS invested in NPS Co., Ltd. (affiliated company accounted for by the equity method) and collaboration agreement with Nippon Pulse Motor Co., Ltd.
PSS invested in NPS Co., Ltd. (affiliated company accounted for by the equity method) and collaboration agreement with Nippon Pulse Motor Co., Ltd.
Transitioned to the JASDAQ Standard Market.
- 2010 : October : We moved to JASDAQ(Standard) Listed market.
We moved to JASDAQ(Standard) Listed market.
Signed a development agreement with DiaSorin for a molecular diagnostic device using the LAMP method.
- 2011 : April : PSS reaches an agreement with DiaSorin to develop a molecular diagnostic analyzer for LAMP.
PSS reaches an agreement with DiaSorin to develop a molecular diagnostic analyzer for LAMP.
Signed a contract with Abbott for the development of fully automated pretreatment devices for automated bacterial testing systems
- 2012 : March : PSS reaches Development Agreement with Abbott.
PSS reaches Development Agreement with Abbott.
Signed a joint development and sales supply agreement with ELITechGroup for the fully automated gene analysis system "geneLEAD"
- 2013 : April : PSS and ELITech Group enter into a Joint Development, Distribution and Supply Agreement on PSS's 'geneLEAD', a fully automated, sample-to-result, Real-Time PCR analyzer.
PSS and ELITech Group enter into a Joint Development, Distribution and Supply Agreement on PSS's 'geneLEAD', a fully automated, sample-to-result, Real-Time PCR analyzer.
Transitioned to the Tokyo Stock Exchange JASDAQ Standard Market due to the integration of the Osaka Securities Exchange and Tokyo Stock Exchange
- July : Due to the merger between (OSE) Hercules and JASDAQ, PSS was listed on TSE JASDAQ (Standard) market.
Signed a supply and sales agreement with LG Life Sciences in Korea regarding the fully automated gene analysis system "geneLEAD"
Signed an OEM agreement with Roka in the United States for genetic testing systems for food inspection
- 2014 : May : PSS and Roka Bioscience enter into an OEM Agreement on Development of Automated Molecular Diagnostics System.
PSS and Roka Bioscience enter into an OEM Agreement on Development of Automated Molecular Diagnostics System.
Signed a product supply agreement for specimen pretreatment systems for Abbott
- October : PSS reaches Agreement to Supply Abbott with Two Types of Sample Prep System.
PSS Odate Reagent Center operational
- November : Started operation of PSS Odate Reagent Center
Signed an OEM supply agreement with ELITechGroup for the fully automated genetic diagnostic system "geneLEAD XII"
- December : PSS and ELITechGroup reach OEM Agreement on 'geneLEAD XII' a fully automated, sample-to-result, Real-Time PCR system.
Changed market to Tokyo Stock Exchange Mothers
- 2015 : September : We moved to Mothers Listed market.
We moved to Mothers Listed market.
Acquired additional shares of NPS Inc. and made it a wholly owned subsidiary
- 2016 : June : PSS obtained additional stocks of NPS Co., Ltd. and made it a wholly owned subsidiary.
PSS obtained additional stocks of NPS Co., Ltd. and made it a wholly owned subsidiary.
Capital and business alliance with Hitachi High-Technologies Corporation, issuance of new shares through third-party allotment
- 2017 : May : Capital & business alliance with Hitachi High-Technologies Corporation, issuance of new shares through third-party allotment.
Capital & business alliance with Hitachi High-Technologies Corporation, issuance of new shares through third-party allotment.
Received a letter of appreciation from the French Ambassador to Japan for supplying fully automated PCR testing systems
- 2020 : April : Received a letter of appreciation from the French Ambassador to Japan for the supply of a fully automated PCR testing system.
Received a letter of appreciation from the French Ambassador to Japan for the supply of a fully automated PCR testing system.
Adopted the subsidy for domestic investment promotion projects for supply chain countermeasures
- July : Received 'Subsidy for Domestic Investment Promotion Project for Supply Chain Measures'.
Launched sales of fully automated PCR testing devices and PCR reagents for COVID-19 (SARS-CoV-2) testing in Japan
- August : Fully automated PCR testing system and PCR reagents for 'COVID-19 (SARS-CoV-2)' test are launched in Japan.
Received the Nikkei Excellent Product & Service Award: Nikkei Industry Newspaper Award for the fully automated PCR testing system "Elite Ingenious" and the 63rd Top 10 New Products Award: Nikkan Kogyo Shimbun for "GeneRead Eight" in 2020
Receives the NIKKEI BUSINESS DAILY Award for the Nikkei Superior Products and Services Award 2020 for the fully automated PCR testing system "ELITe InGenius" and the THE NIKKAN KOGYO SHIMBUN Award 63rd New Product Award 2020 for "geneLEAD VIII".
Registered PSS Shinjuku Laboratory (Shinjuku-ku, Tokyo) as a sanitary inspection office (closed in May 2024)
Transitioned to the Growth Market due to review of Tokyo Stock Exchange market classification
Moves to the Growth Market in accordance with the revision of the Tokyo Stock Exchange's market classification.
Commissioned the second factory of PSS Odate Reagent Center
Established a joint venture, PF・BioLine, with Ferrotec Holdings Corporation (liquidation completed in March 2025)
Absorbed and succeeded the reagent manufacturing and consumables manufacturing business operated by NPS Inc. through a simplified absorption-type company split
Assumed the reagent and consumables manufacturing business of NPS Co., Ltd. through a simplified absorption-type split.
§07
News
25 ARTICLES
Precision System Science Consolidated Financial Statements for the Third Quarter of the Fiscal Year Ending September 2026 (Japanese GAAP)
Precision System Science Co., Ltd. has released consolidated financial statements for the three-month period ending September 30, 2026 (July 1 to September 30, 2026). This report is prepared in accordance with Japanese GAAP and presents an overview of key financial metrics and performance.
FY2026 Consolidated Financial Results
For the fiscal year ended June 30, 2026, net sales rose 11.2% year over year to ¥5,216 million. The company reported operating profit of ¥201 million, ordinary profit of ¥155 million, and profit attributable to owners of the parent of ¥394 million, compared with losses in the previous fiscal year.
Precision System Science Reports FY2026 Results
Precision System Science reported consolidated revenue of approximately ¥5.2 billion for fiscal 2026, up year over year. Operating profit was approximately ¥200 million, down year over year. Net income was approximately ¥155 million, turning profitable from a loss the previous year.
Nine-Month Results to March 31, 2026
Net sales rose to ¥3,778 million for the nine months ended March 31 2026, up from ¥3,462 million in the same period last year. Operating profit fell to ¥134 million from ¥83 million, while ordinary profit and profit attributable to owners were ¥109 million and ¥201 million, respectively, both lower than the prior year. Basic earnings per share were ¥7.37, with no diluted EPS disclosed.
Precision System Science's 9-month results for the fiscal year ending March 2026
During the nine months of the fiscal year ending March 2026, revenue was 3,778 million yen, an increase of 9.1% year-over-year, and net profit was 109 million yen.
Six-Month Results to Dec 31, 2025
For the six months ended December 31 2025, the company reported net sales of ¥2,534 million, up from ¥2,197 million in the prior year, and an operating profit margin of 15.3 %. Ordinary profit turned positive at ¥84 million, compared with a ¥111 million loss in the same period last year, while profit attributable to owners of parent rose to ¥69 million from a ¥119 million loss. Basic earnings per share were ¥2.27, versus a loss of ¥5.65 in the previous year.
Precision System Science's June 2025 Semi-Annual Financial Results
The consolidated performance for the six months ending December 2025 was sales of 2,534 million yen and operating profit of 84 million yen, an increase compared to the same period last year. Net profit was 69 million yen, with basic earnings per share of 2.27 yen.
Precision System Science's March 2025 Quarterly Results
In the first quarter of FY2025, sales increased year-over-year, operating profit improved, but net profit remained a loss.
Precision System Science Address Update
The address display of Odate Regent Center in Odate City, Akita Prefecture has been updated, but there are no changes to the location or contact information.
Nine-Month Results to March 31, 2025
Net sales rose to ¥3,462 million in the nine months ended March 31, 2025, up from ¥2,941 million in the same period last year. Operating profit margin improved to 17.7% from a negative 30.1% in the prior year. Ordinary profit and profit attributable to owners of parent were ¥(83) million and ¥(97) million, respectively, compared with ¥(639) million and ¥(685) million in the prior year. Basic earnings per share were ¥(6.75) versus ¥(23.81) in the prior year.
§08
Public records
GOV
National Tax Agency basic information9040001037483
Source: National Tax Agency Corporate Number Publication Site, basic three items